As I said they all but named biomarin in the investor day as an interested party. With CAP 51 naming them too, I have every expectation they are auctioning off a slice of the MPS pie with high sales price/low COG - BioMarin isn’t turning a profit.
Looking at the history of changes in 002 trial and the right range of dosing I think the FDA are quite convinced on efficacy in OA.
research reports and media, page-2399
-
- There are more pages in this discussion • 2,013 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PAR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
24.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $85.70M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 8000 | 25.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 25.5¢ | 46689 | 5 |
View Market Depth
| Last trade - 09.28am 02/09/2024 (20 minute delay) ? |
| PAR (ASX) Chart |
Day chart unavailable